Chronic Hepatitis B Infection

Infectious Diseases
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

PharmaEssentia
PharmaEssentiaMA - Burlington
1 program
1
P1101 + Nivolumab + EntecavirPhase 1Small Molecule1 trial
Active Trials
NCT04638439CompletedEst. May 2025

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
PharmaEssentiaP1101 + Nivolumab + Entecavir

Clinical Trials (1)

NCT04638439PharmaEssentiaP1101 + Nivolumab + Entecavir

The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection

Start: Aug 2022Est. completion: May 2025
Phase 1Completed

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space